---
figid: PMC5876695__41236_2017_7_Fig3_HTML
figtitle: Network model of oncogenic signal transduction in ER+ breast cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5876695
filename: 41236_2017_7_Fig3_HTML.jpg
figlink: /pmc/articles/PMC5876695/figure/Fig3/
number: F3
caption: 'Network model of oncogenic signal transduction in ER+ breast cancer. The
  nodes are colored according to the pathway they are part of: RTK signaling, PI3K
  signaling, MAPK pathway, AKT pathway, mTORC1 pathway, ER signaling, cell-death signaling
  (apoptosis) and cell-cycle regulation (proliferation). The network also includes
  selected drugs of interest in the context of breast cancer: Alpelisib (PI3K inhibitor),
  Ipatasertib (AKT inhibitor), Fulvestrant (ER inhibitor), Palbociclib (CDK4/6 inhibitor),
  Everolimus (mTOR inhibitor), Trametinib (MEK inhibitor), and Neratinib (HER1/2 inhibitor).
  For clarity of the figure, we merge certain nodes into a single node when there
  is no ambiguity; for example, a node denoting a transcript is merged with the protein
  it codes, e.g., BCL2 and BCL2_T (for BCL2 transcript) are shown as BCL2. The full
  list of network nodes is indicated in Additional File'
papertitle: A network modeling approach to elucidate drug resistance mechanisms and
  predict combinatorial drug treatments in breast cancer.
reftext: Jorge Gómez Tejeda Zañudo, et al. Cancer Converg. 2017;1(1):5.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8650525
figid_alias: PMC5876695__F3
figtype: Figure
redirect_from: /figures/PMC5876695__F3
ndex: db9a7d64-df1a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5876695__41236_2017_7_Fig3_HTML.html
  '@type': Dataset
  description: 'Network model of oncogenic signal transduction in ER+ breast cancer.
    The nodes are colored according to the pathway they are part of: RTK signaling,
    PI3K signaling, MAPK pathway, AKT pathway, mTORC1 pathway, ER signaling, cell-death
    signaling (apoptosis) and cell-cycle regulation (proliferation). The network also
    includes selected drugs of interest in the context of breast cancer: Alpelisib
    (PI3K inhibitor), Ipatasertib (AKT inhibitor), Fulvestrant (ER inhibitor), Palbociclib
    (CDK4/6 inhibitor), Everolimus (mTOR inhibitor), Trametinib (MEK inhibitor), and
    Neratinib (HER1/2 inhibitor). For clarity of the figure, we merge certain nodes
    into a single node when there is no ambiguity; for example, a node denoting a
    transcript is merged with the protein it codes, e.g., BCL2 and BCL2_T (for BCL2
    transcript) are shown as BCL2. The full list of network nodes is indicated in
    Additional File'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tie
  - Ras85D
  - InR
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - MKP-4
  - p38b
  - rl
  - Akt
  - Crtc
  - Pten
  - ras
  - Ras64B
  - Pdk1
  - pim
  - Myc
  - DCTN6-p27
  - dap
  - CG9588
  - Cdk4
  - Tsc
  - Tsc1
  - CycD
  - CycE
  - Cdk2
  - PRAS40
  - S6k
  - rb
  - eIF4E7
  - eIF4E4
  - eIF4E5
  - eIF4E3
  - eIF4E1
  - Debcl
  - cass
  - ebi
  - E2f2
  - E2f1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPTOR
  - ERBB3
  - IGF1R
  - FOXA1
  - PTEN
  - KRAS
  - HRAS
  - NRAS
  - PDK1
  - PDPK1
  - MAPKAP1
  - RICTOR
  - MLST8
  - PIM1
  - PIM2
  - PIM3
  - KMT2D
  - MYC
  - SGK1
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CDK6
  - CDK4
  - SLC12A3
  - TSC1
  - TESC
  - TSC2
  - CDK2
  - AKT1S1
  - FOXO3
  - RPS6KB1
  - EIF4A2
  - EIF4E
  - EIF4G1
  - BCL2L11
  - BCL2
  - BAD
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - Neratinib
  - Trametinib
  - Cancer
---
